Indoco Remedies Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Indoco Remedies de 99.1% y 12.2% respectivamente, mientras que el BPA crecerá en un 126.7% al año.
Información clave
99.1%
Tasa de crecimiento de los beneficios
126.68%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 18.3% |
| Tasa de crecimiento de los ingresos | 12.2% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 29 Jul 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results
Indoco Remedies Limited ( NSE:INDOCO ) shareholders are probably feeling a little disappointed, since its shares fell...The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Recent updates
Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results
Indoco Remedies Limited ( NSE:INDOCO ) shareholders are probably feeling a little disappointed, since its shares fell...
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2028 | 23,122 | 1,126 | 812 | N/A | 4 |
| 3/31/2027 | 20,300 | 644 | 1,656 | N/A | 4 |
| 6/30/2026 | 18,732 | 56 | N/A | N/A | N/A |
| 3/31/2026 | 18,453 | -951 | 447 | 1,922 | N/A |
| 12/31/2025 | 17,599 | -1,139 | N/A | N/A | N/A |
| 9/30/2025 | 17,251 | -1,105 | -960 | 1,408 | N/A |
| 6/30/2025 | 16,713 | -1,122 | N/A | N/A | N/A |
| 3/31/2025 | 16,649 | -737 | -2,612 | 949 | N/A |
| 12/31/2024 | 17,243 | -107 | N/A | N/A | N/A |
| 9/30/2024 | 17,732 | 321 | -3,076 | 2,220 | N/A |
| 6/30/2024 | 18,223 | 767 | N/A | N/A | N/A |
| 3/31/2024 | 18,173 | 985 | -2,706 | 1,554 | N/A |
| 12/31/2023 | 17,958 | 1,016 | N/A | N/A | N/A |
| 9/30/2023 | 17,356 | 1,134 | -911 | 1,442 | N/A |
| 6/30/2023 | 16,869 | 1,281 | N/A | N/A | N/A |
| 3/31/2023 | 16,686 | 1,423 | -284 | 1,788 | N/A |
| 12/31/2022 | 16,496 | 1,569 | N/A | N/A | N/A |
| 9/30/2022 | 16,084 | 1,617 | 85 | 1,703 | N/A |
| 6/30/2022 | 15,622 | 1,537 | N/A | N/A | N/A |
| 3/31/2022 | 15,408 | 1,548 | 485 | 1,738 | N/A |
| 12/31/2021 | 14,368 | 1,393 | N/A | N/A | N/A |
| 9/30/2021 | 14,110 | 1,317 | 257 | 1,391 | N/A |
| 6/30/2021 | 13,524 | 1,157 | N/A | N/A | N/A |
| 3/31/2021 | 12,415 | 930 | 54 | 822 | N/A |
| 12/31/2020 | 12,084 | 734 | N/A | N/A | N/A |
| 9/30/2020 | 11,654 | 571 | 387 | 931 | N/A |
| 6/30/2020 | 11,298 | 393 | N/A | N/A | N/A |
| 3/31/2020 | 11,066 | 241 | N/A | 1,228 | N/A |
| 12/31/2019 | 10,909 | 302 | N/A | N/A | N/A |
| 9/30/2019 | 10,640 | 264 | N/A | N/A | N/A |
| 6/30/2019 | 10,071 | 111 | N/A | N/A | N/A |
| 3/31/2019 | 9,684 | -29 | N/A | 1,321 | N/A |
| 3/31/2018 | 10,424 | 412 | N/A | 1,227 | N/A |
| 3/31/2017 | 10,968 | 771 | N/A | 886 | N/A |
| 3/31/2016 | 10,081 | 819 | N/A | 1,122 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (99.1% al año) de INDOCO es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (99.1% al año) de INDOCO crezcan más rápidamente que el mercado Indian (16.8% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de INDOCO crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (12.2% al año) de INDOCO crezcan más rápidamente que los del mercado Indian (11.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 12.2% al año) de INDOCO crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de INDOCO se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/18 05:04 |
| Precio de las acciones al final del día | 2026/08/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Indoco Remedies Limited está cubierta por 14 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |